Chandra Ramanathan Email & Phone Number

Cambridge, MA, US

Washington, District Of Columbia, US

Washington, District Of Columbia, US

Belmont, MA, US

Research and Innovation Committee member

Cambridge, Massachusetts, US

• Chairperson of innovation services subcommittee looking into novel ways of accelerating innovation in the Boston ecosystem.
• Launched “Center for Regulatory Excellence” and established new mentorship programs to support new start-ups.

• Work with key investigators to identify and advance technologies towards commercialization.
• Partner with members of the innovation team on specific initiatives and provide pharma-specific translational insights

Leverkusen, North Rhine-Westphalia, DE

• Chaired the Open Innovation Committee (OIC) responsible for evaluation and investment recommendations for early-stage therapeutic opportunities. Manages an annual budget of > €75 million investing in 50+ partnerships.
• Led a co-creation process to identify breakthrough technologies across the globe leading to new company creation or collaboration.
• Managed public-private partnership team focusing on complex healthcare challenges and advancing new science (> €100 million in investment).
• Oversaw the Open Innovation Centers (OICs) around the world (US, Europe, Japan, China, and Singapore) focusing on ecosystem engagement and access to early innovation.

Leverkusen, North Rhine-Westphalia, DE

• Built an innovative product portfolio with key academic partners and impact pipeline. Initiated 4 major partnerships (> €140 million investment and > 100 FTEs) – Broad Institute (Oncology and Cardiovascular).
• Led external scientific leadership activities by partnering with patient-advocacy and scientific organizations (AACR, AHA and SRI – Society for Reproductive Investigation).

• Global lead for external Innovation within Bayer AG Innovation Strategy: Led a senior group of functional heads to develop innovative sourcing strategies from VC engagements, open innovation/crowdsourcing models and.
• Provided strategic insights as commentaries to the Bayer Board of Management on portfolio strategy – R&D, strategic investments, and key business issues.

Leverkusen, North Rhine-Westphalia, DE

• Global Launch Team Leader – Aliqopa (Copanlisib): Led a cross-functional team and across key markets (US, EU, Japan, Asia-Pac, LatAm) to develop the Aliqopa launch plan including brand strategy and implementation.
• Head, Global Oncology Pipeline Marketing: Close partnership with Global Drug Discovery (GDD) and Global Development (GD) to advance Bayer oncology portfolio from 2 clinical-stage assets to 15 assets, with four of them.
• Companion Diagnostics Strategy and Value proposition: Commercial lead within product teams to develop suitable CDx strategy for internal programs and commercialization/business models to collaborate with partner.

New York, New York, US

• Bosulif (Bosutinib) Global Brand Team (CML - Phase III and Breast - Phase II): Global brand team lead for bosutinib; created launch commercialization plans, life cycle management, and scientific publication strategies.
• Oncology New Product Development: Led the global commercial strategy team (R&D, regulatory, pricing and market access) to develop new products that reflect customer requirements and optimal access.

Lawrence Township, NJ, US

• Business and Competitive Intelligence: Led the Global Business Intelligence and Strategy team to support brand planning, licensing/business development and strategic decision making.
• Oncology (Sprycel) and Immunology (Orencia) Marketing: Member of the Sprycel and Orencia launch teams. Contributed to the pre-launch strategy and launch/LCM of Sprycel and Orencia in US and global markets.

Lawrence Township, NJ, US

• CNS Licensing and business development: Led the identification and evaluation of potential CNS compounds/technology opportunities and developed a new due diligence methodology. Initiated partnership discussions leading.
• Asia/Pacific Business Development: Led the identification and subsequent follow-up of key early-stage compound opportunities in Japan, Singapore, India, and China. Authored a white paper on early stage pharmaceutical.

Lawrence Township, NJ, US

• Neuroscience Disease Strategy Team: Member of the Neuroscience disease strategy team that created internal scientific and commercial strategy and identified new licensing and business development options for.
• Cardiovascular Biomarker Strategy: Identified Bradykinin pathway biomarkers to select patient sub-population susceptible to angioedema observed in Vanlev clinical trials. The results were incorporated into the NDA.
• Discovery Working Groups: Served as a contributing member of several drug discovery teams in neuroscience, oncology, immunology, virology, CV-metabolics and dermatology. Led the GPCR target team that provided novel.

Mba, Finance And Management

Ph.D., Bioinformatics/Genomics

M.Pharm, Pharmacy

Bs Pharmacy, Pharmacy

Education record